Home > Insider Trading > Biomarin Pharmaceutical Inc

Biomarin Pharmaceutical Inc (BMRN)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
61 - 70
Next >>

Is BioMarin Pharmaceutical Inc. (BMRN) A Good Stock To Buy?

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...

Keep Reading →

December 7th, 2021 - Hedge Funds News

10 Healthcare and Software Stocks to Buy According to Michel Massoud’s Melqart Asset Management

In this article, we take a look at the 10 healthcare and software stocks to buy according to Michel Massoud’s Melqart Asset Management.

Keep Reading →

October 27th, 2021 - Hedge Fund Analysis Hedge Funds News

5 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors

In this article, we will discuss 5 biotech and pharmaceutical stocks to buy according to Palo Alto Investors based on Q2 holdings of the fund.

Keep Reading →

October 21st, 2021 - Hedge Funds News

5 Best Genomic Stocks to Buy Now

In this article, we will take a look at the 5 best genomic stocks to buy now.

Keep Reading →

October 19th, 2021 - Hedge Funds News

Hedge Funds Are Nibbling On BioMarin Pharmaceutical Inc. (BMRN)

A whopping number of 13F filings filed with U.S.

Keep Reading →

October 4th, 2021 - Hedge Funds News

10 Stocks Stanley Druckenmiller is Selling

In this article, we discuss the 10 stocks Stanley Druckenmiller is selling.

Keep Reading →

July 12th, 2021 - Hedge Funds News

Is BioMarin Pharmaceutical Inc. (BMRN) A Good Stock To Buy?

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...

Keep Reading →

June 21st, 2021 - Hedge Funds News

Here's Why ClearBridge Sold its BioMarin Pharmaceutical (BMRN) Position

ClearBridge Investments, an investment management firm, published its “SMID Cap Growth Strategy” first quarter 2021 investor letter – a copy of which can be downloaded here.

Keep Reading →

June 2nd, 2021 - Hedge Fund Investor Letters News